153 e-Letters

published between 2014 and 2017

  • Signficance of Inverse Prognostic Value of Post-PCI FFR in Patients with NSTEMI
    Adnan Nadir

    I read the article by Kasula and colleagues with great interest. I firmly believe that this is a novel finding and of great clinical significance (1).

    Utility of Fractional flow reserve (FFR) is firmly established in stable coronary artery disease but has been widely debated in patients with acute MI particularly in the culprit vessel (2, 3). FFR measurements require maximal coronary hyperaemia which may be les...

    Show More
  • Inverse Prognostic Value of Post-PCI FFR in Patients with NSTEMI
    Marco Canepa

    We thank Ripley and colleagues for their interest in our paper and agree that T1 mapping with CMR is an emerging imaging biomarker that is increasingly being investigated for its potential role in hypertrophic cardiomyopathy and cardiac hypertrophy in general. Convincing data have been published concerning hypertensive heart disease(Hinojar et al., 2015), hypertrophic and dilated cardiomyopathy (Puntmann et al., 2013),...

    Show More
  • Expediating the pathway to SVT ablation
    Claire E.P. Brough

    Honarbakhsh et al should be congratulated upon their innovative research in improving the care for patients with arrhythmias. Their paper not only demonstrates an effective community treatment strategy but importantly is cost effective during the current austerity. Potential further cost savings and enhanced patient experiences could be anticipated by encouraging General Practitioners to subsequently refer patients wishi...

    Show More
  • Multilevel analysis of variance and hospital performance in heart failure management
    Nermin M. Ghith

    Dear Editor,

    We have read with interest the article written by Emdin et al (1) using multilevel regression analysis of variance to investigate hospital performance for heart failure management. We were pleased to note that the authors apply and refer to our previous methodological work concerning the use of the Intraclass Correlation (ICC) and Median Odds Ratio (MOR).(2) However, the authors did not consider a re...

    Show More
  • T1 Mapping with CMR: an emerging clinical biomarker.
    David P. Ripley

    Dear Editor,

    We read the educational review on distinguishing ventricular septal bulge (VSB) versus hypertrophic cardiomyopathy (HCM) by Canepa et al[1] with great interest. The authors recognise the increasingly established role of cardiovascular magnetic resonance (CMR) in the assessment of this difficult diagnostic dilemma. They describe the gold standard role of CMR in the quantification of myocardial mass,...

    Show More
  • Microcirculation impairment in acute coronary syndrome: It is not always the same story
    Matteo Tebaldi

    We read with great interest the elegant work of Kasula et al. recently published on Heart [1]. The Authors showed that fractional flow reserve (FFR) may be an effective tool to discriminate the long-term functional outcome after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) [1]. This retrospective study included exclusively ACS patients for whom FFR evaluation resulted "flow lim...

    Show More
  • Re Larsson et al, Chocolate consumption adn risk fo myocardial infarction: a propspective stusy and meta-analysis
    Barbara J Boucher

    Comment to the Heart Journal website

    re Larsson et al, Chocolate consumption and risk of myocardial infarction: a prospective study and meta-analysis. The findings of Larsson et al are fascinating and in line with earlier reports of cardio-protective effects of chocolate consumption, especially of dark chocolate. Having noticed this in the literature, a colleague and I were inspired to measure the vitamin D con...

    Show More
  • Re:It is important to distinguish between HFrEF and HFpEF when interpreting these data
    Brian J Lipworth

    We would like to thank Dr Cunnington for his interest in our study and raising some potentially interesting points . We do not have a breakdown of patients with heart failure ( HF) who had either preserved (HFpEF) or reduced ejection fraction (HFrEF) . Since beta-blockers only have a licensed indication for HFrEF on the basis of an echocardiogram , we do not believe that this is likely to be a relevant factor withi...

    Show More
  • Impact of Beta-blocker on The Outcome of Takotsubo Cardiomyopathy
    Ibrahim El-Battrawy

    The article by Isogai et al. published in Heart (1) discuss the use of beta-blockers in patients diagnosed and admitted with takotsubo cardiomyopathy (TTC).

    Although no effective guidelines have been prescribed for the treatment of TTC, it is suggested that a parable could be drawn by comparing the use of beta-blocker and angiotensin-converting-enzyme inhibitors in these patients with that of control subjects a...

    Show More
  • It is important to distinguish between HFrEF and HFpEF when interpreting these data
    Colin Cunnington

    In this interesting article, Lipworth and colleagues report that beta -blockers are underused in patients with heart failure (HF) and COPD, compared to those with HF alone. However, they do not quote the proportion of "HF" patients within their dataset who had HF with reduced ejection fraction (HFrEF; left ventricular ejection fraction (LVEF) <40%) and HF with preserved ejection fraction (HFpEF; LVEF >50%). This d...

    Show More